Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease

Abe, Masanori; Miyake, Teruki; Kuno, Atsushi; Imai, Yumiko; Sawai, Yoshiyuki; Hino, Keisuke; Hara, Yuichi; Hige, Shuhei; Sakamoto, Michiie; Yamada, Gotaro; Kage, Masayoshi; Korenaga, Masaaki; Hiasa, Yoichi; Mizokami, Masashi; Narimatsu, Hisashi

doi:10.1007/s00535-014-1007-2

Cited by 158 publications

(208 citation statements)

References 35 publications

Supporting

Mentioning

188

Contrasting

Order By: Relevance

“…In addition, WFA + -M2BP is reported to be a reliable marker of hepatic fibrosis and prognosis in patients with primary biliary cirrhosis and nonalcoholic fatty liver disease. 16,17 …”

Section: Introductionmentioning

confidence: 99%

Use of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B Virus

Heo

Kim²,

Park

et al. 2016

Medicine

View full text Add to dashboard Cite

Wisteria floribunda agglutinin-positive human Mac-2 binding protein (WFA+-M2BP) is a serologic marker corresponding with degree of hepatic fibrosis. We evaluated its accuracy in assessing hepatic fibrosis and in predicting the risk of developing hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB).In a 5-year period (2009–2013), a total of 95 CHB patients with available serum WFA+-M2BP assay and transient elastography assessment [to assess liver stiffness (LS)] who had undergone liver biopsy were recruited for retrospective analysis.Areas under the receiver operating characteristic curve for predicting fibrosis stages via serum WFA+-M2BP level were as follows: ≥F2, 0.688; ≥F3, 0.694; and F4, 0.704 (all P < 0.05). During the follow-up period (median, 45 months), HCC developed in 7 patients (7.4%). In patients with HCC, age, use of antiviral therapy, test parameters (HBV DNA, WFA+-M2BP, and LS determinations), and histologic stage of fibrosis were all significantly greater than in those free of HCC, whereas platelet count was significantly lower (all P < 0.05). On multivariate analysis, WFA+-M2BP was found independently predictive of emergent HCC [hazard ratio (HR) = 2.375; P = 0.036], although LS and histologic stage of fibrosis were not (P > 0.05). Risk of developing HCC was significantly greater in patients with high WFA+-M2BP levels (≥1.8) (adjusted HR = 11.5; P = 0.025). Cumulative incidence rates of HCC were also significantly higher in patients with high (vs. low) levels of WFA+-M2BP (log-rank test, P = 0.016).WFA+-M2BP determination significantly reflected degree/extent of hepatic fibrosis and independently predicted the risk of developing HCC in patients with CHB.

show abstract

“…In addition, WFA + -M2BP is reported to be a reliable marker of hepatic fibrosis and prognosis in patients with primary biliary cirrhosis and nonalcoholic fatty liver disease. 16,17 …”

Section: Introductionmentioning

confidence: 99%

Use of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B Virus

Heo

Kim²,

Park

et al. 2016

Medicine

View full text Add to dashboard Cite

show abstract

“…Higher qHBsAg level is correlated with both HDV-RNA levels and necroinflammatory activity of hepatocytes in HDV infection [16]. WFA+-M2BP has been reported to be a non-invasive, rapid, useful marker for predicting liver fibrosis in several chronic liver diseases [17][18][19][20]. Yet whether M2BPGi level can be useful for determining liver fibrosis in patients with chronic hepatitis D remains unknown.…”

Section: Discussionmentioning

confidence: 99%

“…They reported that serum WFA + -M2BP level represents a reliable non-invasive marker for liver fibrosis in patients with chronic hepatitis B, C, non-alcoholic fatty liver disease and primary biliary cirrhosis [17][18][19][20]. Therefore, the aim of this study was to compare qHBsAg and M2BPGi levels between groups of HBsAg carriers with or without HDV infection.…”

Section: Introductionmentioning

confidence: 99%

Untitled

2016

Cent Asian J Med Sci

View full text Add to dashboard Cite

Objectives: Quantification of serum HBsAg has several clinical significances such as acting as a biomarker for the hepatitis D virus (HDV)-RNA level and necroinflammatory activity in HDV infection. The WFA+-M2BP is a new glyco-biomarker for liver fibrosis. The aim of this study was to compare the quantitative HBsAg and M2BPGi levels between groups of HBV infected patients with or without HDV infection. Methods: Totally, 112 consecutive HBsAg carriers with or without HDV infection (median age 36 vs 38) were enrolled in the study. Serum HBsAg and M2BPGi levels were measured using commercial tests. Results: Mean qHBsAg concentrations were 3.8 ±0.6 log IU/mL and 3.5 ±0.8 log IU/mL in the HDV positive and HDV negative HBsAg carriers, respectively (p = 0.02). Yet 45 patients out of 56 HDV positive patients have HBsAg level >2000 IU/mL whereas only 33 patients in the HBV mono infected group had concentrations this high. The mean M2BPGi was a 1.2 cut-off index (COI) in the HDV negative group vs. 2.1 COI in the HDV positive group (p <0.001). Conclusion: The qHBsAg level was higher in HDV positive patients compared with HDV negative subjects. But qHBsAg levels were higher in the HBeAg positive subjects despite the presence of HDV infection. The mean M2BPGi value in the HDV positive group was higher than in HDV negative subjects.

show abstract

“…The thorough process selected Mac-2 binding protein (M2BP) with a specific glycoform recognized by WFA. This marker was initially described as WFA-binding M2BP or WFA + -M2BP in earlier studies [19,[48][49][50][51], but renamed as M2BPGi upon commercialization of the diagnostic kit in collaboration with a commercial company. M2BP is a secretory protein of about 90 kDa that presents seven N-glycans per monomer.…”

Section: M2bpgi the Liver Fibrosis Glyco-biomarker For Chronic Hepatmentioning

confidence: 98%

“…. M2BPGi is an effective glyco-biomarker for the evaluation of fibrosis in patients with nonalcoholic fatty liver disease [50]. .…”

Section: Large-scale Validation Of M2bpgi In Clinical Studiesmentioning

confidence: 99%

Development of M2BPGi: a novel fibrosis serum glyco-biomarker for chronic hepatitis/cirrhosis diagnostics

Narimatsu

2015

Expert Review of Proteomics

Self Cite

View full text Add to dashboard Cite

Many proteins in the living body are glycoproteins, which present glycans linked on their surface. Glycan structures reflect the degree of cell differentiation or canceration and are cell specific. These characteristics are advantageous in the development of various disease biomarkers. Glycoprotein-based biomarkers (glyco-biomarkers) are developed by utilizing the specific changes in the glycan structure on a glycoprotein secreted from the diseased cells of interest. Therefore, quantification of the altered glycan structures is the key to developing a new glyco-biomarker. Glycoscience is a relatively new area of molecular science, and recent advancement of glycotechnologies is remarkable. In the author's institute, new glycoscience technologies have been designed to be efficiently utilized for the development of new diagnostic agents. This paper introduces a strategy for glyco-biomarker development, which was successfully applied in the development of Wisteria floribunda agglutinin-positive Mac-2 binding protein M2BPGi, a liver fibrosis marker now commercially available for clinical use.

show abstract

Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease

Abstract: Serum WFA(+)-M2BP values are useful for assessing the stage of liver fibrosis in patients with NAFLD.

Cited by 158 publications

References 35 publications

Use of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B Virus

Use of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B Virus

Untitled

Development of M2BPGi: a novel fibrosis serum glyco-biomarker for chronic hepatitis/cirrhosis diagnostics

Contact Info

Product

Resources

About